The TRAIL apoptotic pathway in cancer onset, progression and therapy

By Ricky W. Johnstone, A. Frew, M. Smyth. Nature Reviews. Cancer, 2008

853 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1ae947866bc5f4f81a30000092a3fbcc89fd63d7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Thomas G. Cotter
2. Michael R Hamblin
3. Pawel Mróz

In Molecular Biology

1. Thomas G. Cotter
2. Michael R Hamblin

Citations in the corpus

• Engineering T cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors (2016, neutral): “nanobody synNotch receptor and response elements controlling production of TNF-related apoptosis-inducing ligand (TRAIL), an inducer of apoptosis and a cancer therapeutic (Figure 4B) (Johnstone et al., 2008; Lemke et al., 2014).”
• Apoptosis and cancer: the genesis of a research field (2009, background): “Recombinant TRAIL and TRAIL receptor-specific antibodies are currently being tested in clinical trial”
• Cell Death Pathways in Photodynamic Therapy of Cancer (2011, background): “The most complex example is APO2/TRAIL, which binds five different receptors [73].”